Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Glargine (Lantus) Peptide
Long-acting basal insulin analog for type 1 and type 2 diabetes.
What is Insulin Glargine (Lantus)?
Insulin Glargine (Lantus) is a insulin analog · endocrine peptide studied for type 1 diabetes basal coverage and type 2 diabetes basal insulin therapy. Below is an educational overview of Insulin Glargine (Lantus) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Lantus, Basaglar, Toujeo, Semglee
Type 1 and type 2 diabetes — once-daily basal insulin.
A long-acting insulin that gives you a flat, ~24-hour background level of insulin between meals and overnight.
- •Low blood sugar (hypoglycemia)
- •Weight gain
- •Injection-site reactions
- •Lipohypertrophy
- •Severe hypoglycemia
- •Severe allergic reactions
- •Low potassium
- •Fluid retention/heart failure with TZDs
- •Active hypoglycemia
- •Known insulin glargine hypersensitivity
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Insulin Glargine (Lantus) Mechanism of Action
Recombinant human insulin analog with two arginine residues added to the B-chain and asparagine→glycine at A21, forming microprecipitates at injection site for ~24-hour glucose-lowering activity via insulin receptor activation.
Insulin Glargine (Lantus) Research Areas & Benefits
Insulin Glargine (Lantus) Dosage & Common Research Protocols
Subcutaneous injection once daily at the same time, titrated to fasting glucose.
Protocols summarized for educational reference from published research. Not dosing guidance.
Insulin Glargine (Lantus) — Frequently Asked Questions
Lantus vs Humalog — what is the difference?+
Lantus (insulin glargine U-100) is a long-acting basal insulin analogue providing a relatively flat 24-hour glucose-lowering profile from a once-daily subcutaneous injection; it is used to cover fasting and between-meal glucose. Humalog (insulin lispro) is a rapid-acting mealtime analogue with an onset of ~15 minutes, peak at ~1 hour, and duration of ~4 hours; it is dosed at meals to cover the postprandial glucose rise. In a basal-bolus regimen the two are used together, not interchangeably.
Lantus vs Novolog — how do they differ?+
Lantus (insulin glargine) is a long-acting basal insulin; Novolog (insulin aspart) is a rapid-acting mealtime insulin. They serve different roles in a basal-bolus regimen — Lantus provides 24-hour background coverage, Novolog covers meals. Novolog is pharmacokinetically similar to Humalog (lispro).
Insulin glargine vs lispro — can they be mixed in the same syringe?+
No. Insulin glargine (Lantus) must not be mixed with any other insulin, including rapid-acting analogues such as lispro (Humalog) or aspart (Novolog). Mixing alters the pharmacokinetic profile of glargine and is contraindicated per FDA labeling. Basal-bolus therapy uses separate injections.
Novolog vs Lantus timing — how are they scheduled?+
Lantus (glargine) is typically dosed once daily at the same time each day (morning or bedtime). Novolog (aspart) is dosed within 5–10 minutes of the start of a meal — sometimes immediately after in specific populations. Splitting basal (Lantus) and mealtime (Novolog) coverage is the standard basal-bolus approach.
Insulin Glargine (Lantus) Studies & Cited Research
Treat-to-target insulin glargine trials
Established efficacy and lower nocturnal hypoglycemia vs NPH insulin.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Insulin Glargine (Lantus) Side Effects & Safety Considerations
- •FDA-approved.
- •Hypoglycemia and weight gain are primary risks.
- •Do not mix with other insulins.
Common questions about Insulin Glargine (Lantus)
More Hormonal peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.